<?xml version="1.0" encoding="UTF-8"?><!--Generated by ParsePort ApS--><?instance-generator id="ParsePort XBRL Generator" version="2018.05.24" creationdate="2021-07-08T12:55:33+01:00"?><xbrli:xbrl xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:arr="http://xbrl.dcca.dk/arr" xmlns:sob="http://xbrl.dcca.dk/sob" xmlns:fsa="http://xbrl.dcca.dk/fsa" xmlns:cmn="http://xbrl.dcca.dk/cmn" xmlns:gsd="http://xbrl.dcca.dk/gsd" xmlns:mrv="http://xbrl.dcca.dk/mrv" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xml:lang="en"><link:schemaRef xlink:href="http://archprod.service.eogs.dk/taxonomy/20191001/entryDanishGAAPBalanceSheetAccountFormIncomeStatementByNatureIncludingManagementsReviewStatisticsAndTax20191001.xsd" xlink:type="simple"/><xbrli:unit id="DKK"><xbrli:measure>iso4217:DKK</xbrli:measure></xbrli:unit><xbrli:context id="duration_CY_DUAL_only"><xbrli:entity><xbrli:identifier scheme="http://www.dcca.dk/cvr">36721731</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="duration_CY_DUAL_IdentificationOfAuditorDimension_cmn_auditorIdentifier_only_1"><xbrli:entity><xbrli:identifier scheme="http://www.dcca.dk/cvr">36721731</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period><xbrli:scenario><xbrldi:typedMember dimension="cmn:IdentificationOfAuditorDimension"><cmn:auditorIdentifier>1</cmn:auditorIdentifier></xbrldi:typedMember></xbrli:scenario></xbrli:context><xbrli:context id="duration_CY_DUAL_IdentificationOfMemberOfExecutiveBoardDimension_cmn_memberOfBoardIdentifier_only_1"><xbrli:entity><xbrli:identifier scheme="http://www.dcca.dk/cvr">36721731</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period><xbrli:scenario><xbrldi:typedMember dimension="cmn:IdentificationOfMemberOfExecutiveBoardDimension"><cmn:memberOfBoardIdentifier>1</cmn:memberOfBoardIdentifier></xbrldi:typedMember></xbrli:scenario></xbrli:context><xbrli:context id="duration_CY_only"><xbrli:entity><xbrli:identifier scheme="http://www.dcca.dk/cvr">36721731</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="duration_LY_only"><xbrli:entity><xbrli:identifier scheme="http://www.dcca.dk/cvr">36721731</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="duration_CY_ResultDistributionDimension_fsa_RetainedEarningsMember_only"><xbrli:entity><xbrli:identifier scheme="http://www.dcca.dk/cvr">36721731</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period><xbrli:scenario><xbrldi:explicitMember dimension="fsa:ResultDistributionDimension">fsa:RetainedEarningsMember</xbrldi:explicitMember></xbrli:scenario></xbrli:context><xbrli:context id="duration_LY_ResultDistributionDimension_fsa_RetainedEarningsMember_only"><xbrli:entity><xbrli:identifier scheme="http://www.dcca.dk/cvr">36721731</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period><xbrli:scenario><xbrldi:explicitMember dimension="fsa:ResultDistributionDimension">fsa:RetainedEarningsMember</xbrldi:explicitMember></xbrli:scenario></xbrli:context><xbrli:context id="duration_CY_ClassesOfEquityDimension_fsa_RetainedEarningsMember_only"><xbrli:entity><xbrli:identifier scheme="http://www.dcca.dk/cvr">36721731</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period><xbrli:scenario><xbrldi:explicitMember dimension="fsa:ClassesOfEquityDimension">fsa:RetainedEarningsMember</xbrldi:explicitMember></xbrli:scenario></xbrli:context><xbrli:context id="instant_CY_only"><xbrli:entity><xbrli:identifier scheme="http://www.dcca.dk/cvr">36721731</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="instant_LY_only"><xbrli:entity><xbrli:identifier scheme="http://www.dcca.dk/cvr">36721731</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="instant_CY_ClassesOfEquityDimension_fsa_ContributedCapitalMember_only_start"><xbrli:entity><xbrli:identifier scheme="http://www.dcca.dk/cvr">36721731</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-01-01</xbrli:instant></xbrli:period><xbrli:scenario><xbrldi:explicitMember dimension="fsa:ClassesOfEquityDimension">fsa:ContributedCapitalMember</xbrldi:explicitMember></xbrli:scenario></xbrli:context><xbrli:context id="instant_CY_ClassesOfEquityDimension_fsa_RetainedEarningsMember_only_start"><xbrli:entity><xbrli:identifier scheme="http://www.dcca.dk/cvr">36721731</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-01-01</xbrli:instant></xbrli:period><xbrli:scenario><xbrldi:explicitMember dimension="fsa:ClassesOfEquityDimension">fsa:RetainedEarningsMember</xbrldi:explicitMember></xbrli:scenario></xbrli:context><xbrli:context id="instant_CY_only_start"><xbrli:entity><xbrli:identifier scheme="http://www.dcca.dk/cvr">36721731</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="instant_CY_ClassesOfEquityDimension_fsa_ContributedCapitalMember_only"><xbrli:entity><xbrli:identifier scheme="http://www.dcca.dk/cvr">36721731</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period><xbrli:scenario><xbrldi:explicitMember dimension="fsa:ClassesOfEquityDimension">fsa:ContributedCapitalMember</xbrldi:explicitMember></xbrli:scenario></xbrli:context><xbrli:context id="instant_CY_ClassesOfEquityDimension_fsa_RetainedEarningsMember_only"><xbrli:entity><xbrli:identifier scheme="http://www.dcca.dk/cvr">36721731</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period><xbrli:scenario><xbrldi:explicitMember dimension="fsa:ClassesOfEquityDimension">fsa:RetainedEarningsMember</xbrldi:explicitMember></xbrli:scenario></xbrli:context><xbrli:context id="duration_CY_ClassesOfShortTermLiabilitiesDimension_fsa_OtherShorttermPayablesMember_only"><xbrli:entity><xbrli:identifier scheme="http://www.dcca.dk/cvr">36721731</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period><xbrli:scenario><xbrldi:explicitMember dimension="fsa:ClassesOfShortTermLiabilitiesDimension">fsa:OtherShorttermPayablesMember</xbrldi:explicitMember></xbrli:scenario></xbrli:context><arr:SignatureOfAuditorsDate contextRef="duration_CY_DUAL_only">2021-07-08</arr:SignatureOfAuditorsDate><sob:DateOfApprovalOfAnnualReport contextRef="duration_CY_DUAL_only">2021-07-08</sob:DateOfApprovalOfAnnualReport><fsa:SelectedElementsFromReportingClassC contextRef="duration_CY_DUAL_only">true</fsa:SelectedElementsFromReportingClassC><cmn:IdentificationNumberCvrOfAuditFirm contextRef="duration_CY_DUAL_IdentificationOfAuditorDimension_cmn_auditorIdentifier_only_1">33963556</cmn:IdentificationNumberCvrOfAuditFirm><gsd:PrecedingReportingPeriodStartDate contextRef="duration_CY_DUAL_only">2019-01-01</gsd:PrecedingReportingPeriodStartDate><gsd:PredingReportingPeriodEndDate contextRef="duration_CY_DUAL_only">2019-12-31</gsd:PredingReportingPeriodEndDate><gsd:AddressOfAuditorDistrictName contextRef="duration_CY_DUAL_IdentificationOfAuditorDimension_cmn_auditorIdentifier_only_1">Esbjerg</gsd:AddressOfAuditorDistrictName><gsd:AddressOfAuditorPostCodeIdentifier contextRef="duration_CY_DUAL_IdentificationOfAuditorDimension_cmn_auditorIdentifier_only_1">6701</gsd:AddressOfAuditorPostCodeIdentifier><gsd:AddressOfAuditorStreetBuildingIdentifier contextRef="duration_CY_DUAL_IdentificationOfAuditorDimension_cmn_auditorIdentifier_only_1">8</gsd:AddressOfAuditorStreetBuildingIdentifier><gsd:AddressOfAuditorStreetName contextRef="duration_CY_DUAL_IdentificationOfAuditorDimension_cmn_auditorIdentifier_only_1">Dokken</gsd:AddressOfAuditorStreetName><cmn:NameOfAuditFirm contextRef="duration_CY_DUAL_IdentificationOfAuditorDimension_cmn_auditorIdentifier_only_1">Deloitte Statsautoriseret Revisionspartnerselskab</cmn:NameOfAuditFirm><gsd:RegisteredOfficeOfReportingEntity contextRef="duration_CY_DUAL_only">Kolding</gsd:RegisteredOfficeOfReportingEntity><gsd:AddressOfReportingEntityDistrictName contextRef="duration_CY_DUAL_only">Kolding</gsd:AddressOfReportingEntityDistrictName><gsd:AddressOfReportingEntityPostCodeIdentifier contextRef="duration_CY_DUAL_only">6000</gsd:AddressOfReportingEntityPostCodeIdentifier><fsa:ClassOfReportingEntity contextRef="duration_CY_DUAL_only">Regnskabsklasse B</fsa:ClassOfReportingEntity><cmn:TypeOfAuditorAssistance contextRef="duration_CY_DUAL_only">Erklæring om udvidet gennemgang</cmn:TypeOfAuditorAssistance><gsd:ReportingPeriodEndDate contextRef="duration_CY_DUAL_only">2020-12-31</gsd:ReportingPeriodEndDate><gsd:ReportingPeriodStartDate contextRef="duration_CY_DUAL_only">2020-01-01</gsd:ReportingPeriodStartDate><gsd:AddressOfReportingEntityStreetBuildingIdentifier contextRef="duration_CY_DUAL_only">&lt;br /&gt;&lt;br /&gt;140</gsd:AddressOfReportingEntityStreetBuildingIdentifier><gsd:AddressOfReportingEntityStreetName contextRef="duration_CY_DUAL_only">Haderslevvej</gsd:AddressOfReportingEntityStreetName><gsd:NameOfReportingEntity contextRef="duration_CY_DUAL_only">UR Medicine for Medical Supplies &amp; Laboratories ApS</gsd:NameOfReportingEntity><gsd:IdentificationNumberCvrOfReportingEntity contextRef="duration_CY_DUAL_only">36721731</gsd:IdentificationNumberCvrOfReportingEntity><gsd:IdentificationNumberCvrOfSubmittingEnterprise contextRef="duration_CY_DUAL_only">33963556</gsd:IdentificationNumberCvrOfSubmittingEnterprise><gsd:AddressOfSubmittingEnterprisePostcodeAndTown contextRef="duration_CY_DUAL_only">2300  København S</gsd:AddressOfSubmittingEnterprisePostcodeAndTown><gsd:AddressOfSubmittingEnterpriseStreetAndNumber contextRef="duration_CY_DUAL_only">Weidekampsgade 6</gsd:AddressOfSubmittingEnterpriseStreetAndNumber><gsd:NameOfSubmittingEnterprise contextRef="duration_CY_DUAL_only">Deloitte Statsautoriseret Revisionspartnerselskab</gsd:NameOfSubmittingEnterprise><gsd:InformationOnTypeOfSubmittedReport contextRef="duration_CY_DUAL_only">Årsrapport</gsd:InformationOnTypeOfSubmittedReport><sob:IdentificationOfApprovedAnnualReport contextRef="duration_CY_DUAL_only" xml:lang="en">Executive Board have today considered and approved the annual report of UR Medicine for Medical Supplies &amp; Laboratories ApS for the financial year 01.01.2020 - 31.12.2020.</sob:IdentificationOfApprovedAnnualReport><sob:ConfirmationThatAnnualReportIsPresentedInAccordanceWithRequirementsProvidedForByLegislationAnyStandardsAndRequirementsProvidedByArticlesOfAssociationOrByAgreement contextRef="duration_CY_DUAL_only" xml:lang="en">The annual report is presented in accordance with the Danish Financial Statements Act.</sob:ConfirmationThatAnnualReportIsPresentedInAccordanceWithRequirementsProvidedForByLegislationAnyStandardsAndRequirementsProvidedByArticlesOfAssociationOrByAgreement><sob:ConfirmationThatFinancialStatementGivesTrueAndFairViewOfAssetsLiabilitiesEquityFinancialPositionAndResults contextRef="duration_CY_DUAL_only" xml:lang="en">In my opinion, the financial statements give a true and fair view of the Entity’s financial position at 31.12.2020 and of the results of its operations for the financial year 01.01.2020 - 31.12.2020.</sob:ConfirmationThatFinancialStatementGivesTrueAndFairViewOfAssetsLiabilitiesEquityFinancialPositionAndResults><sob:ManagementsStatementAboutManagementsReview contextRef="duration_CY_DUAL_only" xml:lang="en">I believe that the management commentary contains a fair review of the affairs and conditions referred to
therein.</sob:ManagementsStatementAboutManagementsReview><sob:RecommendationForApprovalOfAnnualReportByGeneralMeeting contextRef="duration_CY_DUAL_only" xml:lang="en">I recommend the annual report for adoption at the Annual General Meeting.</sob:RecommendationForApprovalOfAnnualReportByGeneralMeeting><sob:PlaceOfSignatureOfStatement contextRef="duration_CY_DUAL_only" xml:lang="en">Kolding</sob:PlaceOfSignatureOfStatement><cmn:NameAndSurnameOfMemberOfExecutiveBoard contextRef="duration_CY_DUAL_IdentificationOfMemberOfExecutiveBoardDimension_cmn_memberOfBoardIdentifier_only_1">Imad Mousa Kadhim Al-Mousa</cmn:NameAndSurnameOfMemberOfExecutiveBoard><arr:AddresseeOfAuditorsReportOnExtendedReviewOfFinancialStatements contextRef="duration_CY_DUAL_only" xml:lang="en">To the shareholders of UR Medicine for Medical Supplies &amp; Laboratories ApS</arr:AddresseeOfAuditorsReportOnExtendedReviewOfFinancialStatements><arr:OpinionOnFinancialStatementsExtendedReview contextRef="duration_CY_DUAL_only" xml:lang="en">We have performed an extended review of the financial statements of UR Medicine for Medical Supplies &amp; Laboratories ApS for the
 ​financial year 01.01.2020 - 31.12.2020, which comprise the income statement, 
balance sheet, statement of
 changes in equity and notes, including a summary of significant 
accounting policies. The financial statements
 are prepared in accordance with the Danish Financial Statements Act.

​Based on our extended review, in our opinion, the financial statements give a true and fair view of the Entity’s
​financial position at. 31.12.2020 and of the results of its operations for the 
financial year 01.01.2020 - 31.12.2020 in accordance with the Danish Financial 
Statements Act.</arr:OpinionOnFinancialStatementsExtendedReview><arr:DescriptionOfQualificationsOfFinancialStatementsExtendedReview contextRef="duration_CY_DUAL_only" xml:lang="en">We conducted our extended review in accordance with the assurance engagement standard for small enterprises
as issued by the Danish Business Authority and the standard on extended review of financial statements
prepared in accordance with the Danish Financial Statements Act as issued by FSR - Danish Auditors.
 Our responsibilities under those standards and requirements are further described in the ”Auditor’s responsibilities
 for the extended review of the financial statements” section. We are independent of the Entity in accordance
 with the International Ethics Standards Board for Accountants’ Code of Ethics for Professional Accountants (IESBA Code) and the additional requirements applicable in Denmark, and we have fulfilled our other ethical
 responsibilities in accordance with these requirements. We believe that the evidence we have obtained is
 sufficient and appropriate to provide a basis for our conclusion.</arr:DescriptionOfQualificationsOfFinancialStatementsExtendedReview><arr:StatementOfExecutiveAndSupervisoryBoardsResponsibilityForFinancialStatementsExtendedReview contextRef="duration_CY_DUAL_only" xml:lang="en">Management is responsible for the preparation of financial statements that give a true and fair view in accordance
 with the Danish Financial Statements Act, and for such internal control as Management determines
is necessary to enable the preparation of financial statements that are free from material misstatement,
whether due to fraud or error.

In preparing the financial statements, Management is responsible for assessing the Entity’s ability to continue
as a going concern, disclosing, as applicable, matters related to going concern, and using the going concern basis of accounting unless Management either intends to liquidate the Entity or to cease operations, or has
 no realistic alternative but to do so.</arr:StatementOfExecutiveAndSupervisoryBoardsResponsibilityForFinancialStatementsExtendedReview><arr:StatementOfAuditorsResponsibilityExtendedReview contextRef="duration_CY_DUAL_only" xml:lang="en">Our responsibility is to express a conclusion on the financial statements. This requires that we plan and
perform procedures to obtain limited assurance about our conclusion on the financial statements and that
we also perform specifically required supplementary procedures for the purpose of obtaining additional assurance
 about our conclusion.

An extended review consists of making inquiries, primarily of management and, if appropriate, of other entity
personnel, performing analytical and the specifically required supplementary procedures as well as evaluating
the evidence obtained.

The procedures performed in an extended review are less in scope than in an audit, and accordingly we do
not express an audit opinion on the financial statements.</arr:StatementOfAuditorsResponsibilityExtendedReview><arr:StatementOnManagementsReviewAuditorsReportOnExtendedReviewFinancialStatementsExtendedReview contextRef="duration_CY_DUAL_only" xml:lang="en">Management is responsible for the management commentary.

Our opinion on the financial statements does not cover the management commentary, and we do not express
any form of assurance conclusion thereon.

In connection with our extended review of the financial statements our responsibility is to read the management
commentary and, in doing so, consider whether the management commentary is materially inconsistent
with the financial statements or our knowledge obtained in the extended review or otherwise appears to be
materially misstated.

Moreover, it is our responsibility to consider whether the management commentary provides the information
required under the Danish Financial Statements Act.&lt;br /&gt;Based on the work we have performed, we conclude that the management commentary is in accordance with
financial statements and has been prepared in accordance with the requirements of the Danish Financial
Statements Act. We did not identify any material misstatement of the management commentary.</arr:StatementOnManagementsReviewAuditorsReportOnExtendedReviewFinancialStatementsExtendedReview><arr:SignatureOfAuditorsPlace contextRef="duration_CY_DUAL_only" xml:lang="en">Esbjerg</arr:SignatureOfAuditorsPlace><cmn:NameAndSurnameOfAuditor contextRef="duration_CY_DUAL_IdentificationOfAuditorDimension_cmn_auditorIdentifier_only_1">Anders Rasmussen</cmn:NameAndSurnameOfAuditor><cmn:IdentificationNumberOfAuditor contextRef="duration_CY_DUAL_IdentificationOfAuditorDimension_cmn_auditorIdentifier_only_1">mne34316</cmn:IdentificationNumberOfAuditor><cmn:DescriptionOfAuditor contextRef="duration_CY_DUAL_IdentificationOfAuditorDimension_cmn_auditorIdentifier_only_1">State Authorised Public Accountant</cmn:DescriptionOfAuditor><mrv:DescriptionOfPrimaryActivitiesOfEntity contextRef="duration_CY_DUAL_only" xml:lang="en">Primary activitiesThe Company’s purpose is to do business with articles on health care and according to the Executive Borad’s discretion in business related thereto.</mrv:DescriptionOfPrimaryActivitiesOfEntity><mrv:DescriptionOfDevelopmentInActivitiesAndFinancialAffairs contextRef="duration_CY_DUAL_only" xml:lang="en">Development in activities and financesThe Company’s loss is DKK 299k, which isn’t satisfying.
</mrv:DescriptionOfDevelopmentInActivitiesAndFinancialAffairs><fsa:GrossProfitLoss contextRef="duration_CY_only" decimals="0" unitRef="DKK">-212903</fsa:GrossProfitLoss><fsa:GrossProfitLoss contextRef="duration_LY_only" decimals="0" unitRef="DKK">-876342</fsa:GrossProfitLoss><fsa:OtherFinanceIncome contextRef="duration_CY_only" decimals="0" unitRef="DKK">1720</fsa:OtherFinanceIncome><fsa:OtherFinanceIncome contextRef="duration_LY_only" decimals="0" unitRef="DKK">1654</fsa:OtherFinanceIncome><fsa:RestOfOtherFinanceExpenses contextRef="duration_CY_only" decimals="0" unitRef="DKK">172337</fsa:RestOfOtherFinanceExpenses><fsa:RestOfOtherFinanceExpenses contextRef="duration_LY_only" decimals="0" unitRef="DKK">70955</fsa:RestOfOtherFinanceExpenses><fsa:ProfitLossFromOrdinaryActivitiesBeforeTax contextRef="duration_CY_only" decimals="0" unitRef="DKK">-383520</fsa:ProfitLossFromOrdinaryActivitiesBeforeTax><fsa:ProfitLossFromOrdinaryActivitiesBeforeTax contextRef="duration_LY_only" decimals="0" unitRef="DKK">-945643</fsa:ProfitLossFromOrdinaryActivitiesBeforeTax><fsa:TaxExpense contextRef="duration_CY_only" decimals="0" unitRef="DKK">-85000</fsa:TaxExpense><fsa:TaxExpense contextRef="duration_LY_only" decimals="0" unitRef="DKK">-208000</fsa:TaxExpense><fsa:ProfitLoss contextRef="duration_CY_only" decimals="0" unitRef="DKK">-298520</fsa:ProfitLoss><fsa:ProfitLoss contextRef="duration_LY_only" decimals="0" unitRef="DKK">-737643</fsa:ProfitLoss><fsa:ProfitLoss contextRef="duration_CY_ResultDistributionDimension_fsa_RetainedEarningsMember_only" decimals="0" unitRef="DKK">-298520</fsa:ProfitLoss><fsa:ProfitLoss contextRef="duration_LY_ResultDistributionDimension_fsa_RetainedEarningsMember_only" decimals="0" unitRef="DKK">-737643</fsa:ProfitLoss><fsa:ProfitLoss contextRef="duration_CY_ClassesOfEquityDimension_fsa_RetainedEarningsMember_only" decimals="0" unitRef="DKK">-298520</fsa:ProfitLoss><fsa:ManufacturedGoodsAndGoodsForResale contextRef="instant_CY_only" decimals="0" unitRef="DKK">282917</fsa:ManufacturedGoodsAndGoodsForResale><fsa:ManufacturedGoodsAndGoodsForResale contextRef="instant_LY_only" decimals="0" unitRef="DKK">282917</fsa:ManufacturedGoodsAndGoodsForResale><fsa:Inventories contextRef="instant_CY_only" decimals="0" unitRef="DKK">282917</fsa:Inventories><fsa:Inventories contextRef="instant_LY_only" decimals="0" unitRef="DKK">282917</fsa:Inventories><fsa:ShorttermTradeReceivables contextRef="instant_CY_only" decimals="0" unitRef="DKK">1198527</fsa:ShorttermTradeReceivables><fsa:ShorttermTradeReceivables contextRef="instant_LY_only" decimals="0" unitRef="DKK">2265047</fsa:ShorttermTradeReceivables><fsa:ShorttermReceivablesFromGroupEnterprises contextRef="instant_CY_only" decimals="0" unitRef="DKK">44713</fsa:ShorttermReceivablesFromGroupEnterprises><fsa:ShorttermReceivablesFromGroupEnterprises contextRef="instant_LY_only" decimals="0" unitRef="DKK">42993</fsa:ShorttermReceivablesFromGroupEnterprises><fsa:CurrentDeferredTaxAssets contextRef="instant_CY_only" decimals="0" unitRef="DKK">346000</fsa:CurrentDeferredTaxAssets><fsa:CurrentDeferredTaxAssets contextRef="instant_LY_only" decimals="0" unitRef="DKK">261000</fsa:CurrentDeferredTaxAssets><fsa:OtherShorttermReceivables contextRef="instant_CY_only" decimals="0" unitRef="DKK">2164</fsa:OtherShorttermReceivables><fsa:OtherShorttermReceivables contextRef="instant_LY_only" decimals="0" unitRef="DKK">19</fsa:OtherShorttermReceivables><fsa:ShorttermReceivables contextRef="instant_CY_only" decimals="0" unitRef="DKK">1591404</fsa:ShorttermReceivables><fsa:ShorttermReceivables contextRef="instant_LY_only" decimals="0" unitRef="DKK">2569059</fsa:ShorttermReceivables><fsa:CashAndCashEquivalents contextRef="instant_CY_only" decimals="0" unitRef="DKK">211</fsa:CashAndCashEquivalents><fsa:CashAndCashEquivalents contextRef="instant_LY_only" decimals="0" unitRef="DKK">9463</fsa:CashAndCashEquivalents><fsa:CurrentAssets contextRef="instant_CY_only" decimals="0" unitRef="DKK">1874532</fsa:CurrentAssets><fsa:CurrentAssets contextRef="instant_LY_only" decimals="0" unitRef="DKK">2861439</fsa:CurrentAssets><fsa:Assets contextRef="instant_CY_only" decimals="0" unitRef="DKK">1874532</fsa:Assets><fsa:Assets contextRef="instant_LY_only" decimals="0" unitRef="DKK">2861439</fsa:Assets><fsa:ContributedCapital contextRef="instant_CY_only" decimals="0" unitRef="DKK">50000</fsa:ContributedCapital><fsa:ContributedCapital contextRef="instant_LY_only" decimals="0" unitRef="DKK">50000</fsa:ContributedCapital><fsa:RetainedEarnings contextRef="instant_CY_only" decimals="0" unitRef="DKK">777951</fsa:RetainedEarnings><fsa:RetainedEarnings contextRef="instant_LY_only" decimals="0" unitRef="DKK">1076471</fsa:RetainedEarnings><fsa:Equity contextRef="instant_CY_only" decimals="0" unitRef="DKK">827951</fsa:Equity><fsa:Equity contextRef="instant_LY_only" decimals="0" unitRef="DKK">1126471</fsa:Equity><fsa:Equity contextRef="instant_CY_ClassesOfEquityDimension_fsa_ContributedCapitalMember_only_start" decimals="0" unitRef="DKK">50000</fsa:Equity><fsa:Equity contextRef="instant_CY_ClassesOfEquityDimension_fsa_RetainedEarningsMember_only_start" decimals="0" unitRef="DKK">1076471</fsa:Equity><fsa:Equity contextRef="instant_CY_only_start" decimals="0" unitRef="DKK">1126471</fsa:Equity><fsa:Equity contextRef="instant_CY_ClassesOfEquityDimension_fsa_ContributedCapitalMember_only" decimals="0" unitRef="DKK">50000</fsa:Equity><fsa:Equity contextRef="instant_CY_ClassesOfEquityDimension_fsa_RetainedEarningsMember_only" decimals="0" unitRef="DKK">777951</fsa:Equity><fsa:ShorttermPayablesToGroupEnterprises contextRef="instant_CY_only" decimals="0" unitRef="DKK">1009581</fsa:ShorttermPayablesToGroupEnterprises><fsa:ShorttermPayablesToGroupEnterprises contextRef="instant_LY_only" decimals="0" unitRef="DKK">1697968</fsa:ShorttermPayablesToGroupEnterprises><fsa:ShorttermPayablesToShareholdersAndManagement contextRef="instant_CY_only" decimals="0" unitRef="DKK">2000</fsa:ShorttermPayablesToShareholdersAndManagement><fsa:ShorttermPayablesToShareholdersAndManagement contextRef="instant_LY_only" decimals="0" unitRef="DKK">2000</fsa:ShorttermPayablesToShareholdersAndManagement><fsa:OtherPayablesIncludingTaxPayablesLiabilitiesOtherThanProvisionsShortterm contextRef="instant_CY_only" decimals="0" unitRef="DKK">35000</fsa:OtherPayablesIncludingTaxPayablesLiabilitiesOtherThanProvisionsShortterm><fsa:OtherPayablesIncludingTaxPayablesLiabilitiesOtherThanProvisionsShortterm contextRef="instant_LY_only" decimals="0" unitRef="DKK">35000</fsa:OtherPayablesIncludingTaxPayablesLiabilitiesOtherThanProvisionsShortterm><fsa:ShorttermLiabilitiesOtherThanProvisions contextRef="instant_CY_only" decimals="0" unitRef="DKK">1046581</fsa:ShorttermLiabilitiesOtherThanProvisions><fsa:ShorttermLiabilitiesOtherThanProvisions contextRef="instant_LY_only" decimals="0" unitRef="DKK">1734968</fsa:ShorttermLiabilitiesOtherThanProvisions><fsa:LiabilitiesOtherThanProvisions contextRef="instant_CY_only" decimals="0" unitRef="DKK">1046581</fsa:LiabilitiesOtherThanProvisions><fsa:LiabilitiesOtherThanProvisions contextRef="instant_LY_only" decimals="0" unitRef="DKK">1734968</fsa:LiabilitiesOtherThanProvisions><fsa:LiabilitiesAndEquity contextRef="instant_CY_only" decimals="0" unitRef="DKK">1874532</fsa:LiabilitiesAndEquity><fsa:LiabilitiesAndEquity contextRef="instant_LY_only" decimals="0" unitRef="DKK">2861439</fsa:LiabilitiesAndEquity><fsa:DisclosureOfOtherFinanceIncome contextRef="duration_CY_only" xml:lang="en">1 Other financial income
2020
DKK2019
DKKFinancial income from group enterprises1,7201,6541,7201,654</fsa:DisclosureOfOtherFinanceIncome><fsa:DisclosureOfOtherFinanceExpenses contextRef="duration_CY_only" xml:lang="en">2 Other financial expenses2020
DKK2019
DKKFinancial expenses from group enterprises49,99517,688Other interest expenses84,735Exchange rate adjustments122,3346,187Other financial expenses042,345172,33770,955&lt;br /&gt;2020
DKK2019
DKKFinancial expenses from group enterprises49,99517,688Other interest expenses84,735Exchange rate adjustments122,3346,187Other financial expenses042,345172,33770,955</fsa:DisclosureOfOtherFinanceExpenses><fsa:DisclosureOfTaxExpenses contextRef="duration_CY_only" xml:lang="en">3 Tax on profit/loss for the year2020
DKK2019
DKKChange in deferred tax(85,000)(208,000)(85,000)(208,000)</fsa:DisclosureOfTaxExpenses><fsa:ExplanationOfShorttermLiability contextRef="duration_CY_ClassesOfShortTermLiabilitiesDimension_fsa_OtherShorttermPayablesMember_only" xml:lang="en">4 Other payables2020
DKK2019
DKKOther costs payable35,00035,00035,00035,000</fsa:ExplanationOfShorttermLiability><fsa:DisclosureOfContingentLiabilities contextRef="duration_CY_only" xml:lang="en">5 Contingent liabilitiesThe Entity participates in a Danish joint taxation
 arrangement where MAI Holding Kolding ApS serves as the administration company. According to the joint taxation provisions of
 the Danish Corporation Tax Act, the Entity is therefore liable for income taxes etc for the jointly taxed entities,  and for obligations, if any, relating to the withholding of tax on interest, royalties and dividend for the jointly
 taxed entities. The jointly taxed entities' total known net liability under the joint taxation arrangement is
 disclosed in the administration company's financial statements.</fsa:DisclosureOfContingentLiabilities><fsa:InformationOnReportingClassOfEntity contextRef="duration_CY_DUAL_only" xml:lang="en">This annual report has been presented in accordance with the provisions of the Danish Financial Statements
Act governing reporting class B enterprises with addition of certain provisions for reporting class C.The accounting policies applied to these financial statements are consistent with those applied last year.</fsa:InformationOnReportingClassOfEntity><fsa:AccountingPoliciesAreUnchangedFromPreviousPeriod contextRef="duration_CY_DUAL_only" xml:lang="en">false</fsa:AccountingPoliciesAreUnchangedFromPreviousPeriod><fsa:DescriptionOfMethodsOfRecognitionAndMeasurementBasisOfGrossProfitLoss contextRef="duration_CY_DUAL_only" xml:lang="en">Gross profit or lossGross profit or loss comprises revenue, other operating income and external expenses.</fsa:DescriptionOfMethodsOfRecognitionAndMeasurementBasisOfGrossProfitLoss><fsa:DescriptionOfMethodsOfRecognitionAndMeasurementBasisOfRevenue contextRef="duration_CY_DUAL_only" xml:lang="en">RevenueRevenue from the sale of services is recognised in the income statement when delivery is made to the buyer. Revenue is recognised net of VAT, duties and sales discounts and is measured at fair value of the consider-ation fixed.</fsa:DescriptionOfMethodsOfRecognitionAndMeasurementBasisOfRevenue><fsa:DescriptionOfMethodsOfRecognitionAndMeasurementBasisOfCostOfSales contextRef="duration_CY_DUAL_only" xml:lang="en">Cost of salesCost of sales comprises goods consumed in the financial year measured at cost, adjusted for ordinary
 inventory writedowns.</fsa:DescriptionOfMethodsOfRecognitionAndMeasurementBasisOfCostOfSales><fsa:DescriptionOfMethodsOfRecognitionAndMeasurementBasisOfExternalExpenses contextRef="duration_CY_DUAL_only" xml:lang="en">Other external expensesOther external expenses include expenses relating to the Entity’s ordinary activities, including expenses for premises, stationery and office supplies, administrative costs, marketing costs, etc. This item also includes writedowns of receivables recognised in current assets.</fsa:DescriptionOfMethodsOfRecognitionAndMeasurementBasisOfExternalExpenses><fsa:DescriptionOfMethodsOfRecognitionAndMeasurementBasisOfFinanceIncome contextRef="duration_CY_DUAL_only" xml:lang="en">Other financial incomeOther financial income comprises interest income, including interest income on receivables from group enterprises etc.</fsa:DescriptionOfMethodsOfRecognitionAndMeasurementBasisOfFinanceIncome><fsa:DescriptionOfMethodsOfRecognitionAndMeasurementBasisOfFinanceExpenses contextRef="duration_CY_DUAL_only" xml:lang="en">Other financial expensesOther external expenses include expenses relating to the Entity’s ordinary activities, including expenses for premises, stationery and office supplies, marketing costs, etc.</fsa:DescriptionOfMethodsOfRecognitionAndMeasurementBasisOfFinanceExpenses><fsa:DescriptionOfMethodsOfRecognitionAndMeasurementBasisOfTaxExpenses contextRef="duration_CY_DUAL_only" xml:lang="en">Tax on profit/loss for the yearTax for the year, which consists of current tax for the year and changes in deferred tax, is recognised in the
income statement by the portion attributable to the profit for the year and recognised directly in equity by
 the portion attributable to entries directly in equity.The Entity is jointly taxed with all Danish group enterprises. The current Danish income tax is allocated
 among the jointly taxed entities proportionally to their taxable income (full allocation with a refund
 concerning tax losses).</fsa:DescriptionOfMethodsOfRecognitionAndMeasurementBasisOfTaxExpenses><fsa:DescriptionOfMethodsOfRecognitionAndMeasurementBasisOfInventories contextRef="duration_CY_DUAL_only" xml:lang="en">InventoriesInventories are measured at the lower of cost using the FIFO method and net realisable value.

Cost consists of purchase price plus delivery costs. 

The net realisable value of inventories is calculated as the estimated selling price less completion costs and
costs incurred to execute sale.</fsa:DescriptionOfMethodsOfRecognitionAndMeasurementBasisOfInventories><fsa:DescriptionOfMethodsOfRecognitionAndMeasurementBasisOfReceivables contextRef="duration_CY_DUAL_only" xml:lang="en">ReceivablesReceivables are measured at amortised cost, usually equalling nominal value less writedowns for bad and
doubtful debts.</fsa:DescriptionOfMethodsOfRecognitionAndMeasurementBasisOfReceivables><fsa:DescriptionOfMethodsOfRecognitionAndMeasurementBasisOfTaxPayablesAndDeferredTax contextRef="duration_CY_DUAL_only" xml:lang="en">Deferred taxDeferred tax is recognised on all temporary differences between the carrying amount and the tax-based
 value of assets and liabilities, for which the tax-based value is calculated based on the planned use of each
 asset. 

Deferred tax assets, including the tax base of tax loss carryforwards, are recognised in the balance sheet at
their estimated realisable value, either as a set-off against deferred tax liabilities or as net tax assets.</fsa:DescriptionOfMethodsOfRecognitionAndMeasurementBasisOfTaxPayablesAndDeferredTax><fsa:DescriptionOfMethodsOfRecognitionAndMeasurementBasisOfCashAndCashEquivalents contextRef="duration_CY_DUAL_only" xml:lang="en">CashCash comprises bank deposits.</fsa:DescriptionOfMethodsOfRecognitionAndMeasurementBasisOfCashAndCashEquivalents><fsa:DescriptionOfMethodsOfRecognitionAndMeasurementBasisOfLiabilitiesOtherThanProvisions contextRef="duration_CY_DUAL_only" xml:lang="en">Other financial liabilitiesOther financial liabilities are measured at amortised cost, which usually corresponds to nominal value.</fsa:DescriptionOfMethodsOfRecognitionAndMeasurementBasisOfLiabilitiesOtherThanProvisions><gsd:DateOfGeneralMeeting contextRef="duration_CY_DUAL_only">2021-07-08</gsd:DateOfGeneralMeeting><gsd:NameAndSurnameOfChairmanOfGeneralMeeting contextRef="duration_CY_DUAL_only">Imad Mouse Kadhim Al-Mousa</gsd:NameAndSurnameOfChairmanOfGeneralMeeting></xbrli:xbrl>